FDA’s Change Of Heart On Vytorin Ads
This article was originally published in The Pink Sheet Daily
Executive Summary
Although the campaign had been running for years with no problems, FDA instructed Merck/Schering-Plough to revise the Vytorin DTC ads even as the agency publicly affirmed the utility of the drug.
You may also be interested in...
FDA Shows Limited Progress In Managing DTC Workload, GAO Tells House Panel
House Energy and Commerce panel hearing focuses on DTC ads for Vytorin, Lipitor and Procrit.
FDA Shows Limited Progress In Managing DTC Workload, GAO Tells House Panel
House Energy and Commerce panel hearing focuses on DTC ads for Vytorin, Lipitor and Procrit.
Vytorin Continues To Grow Globally As Schering Seeks Ways To ENHANCE U.S. Sales
Cholesterol franchise is up 6 percent overall as Zetia and Vytorin prescription sales drop 5 percent in the U.S. in the wake of negative trial results.